a year ago

Grey Wolf Therapeutics Raises $50 Million in Series B Extension to Advance Immuno-Oncology and Autoimmune Therapies

  • Grey Wolf Therapeutics, a UK-based clinical-stage biotech company specializing in antigen modulation therapies, secured $50 million in Series B extension funding, bringing the total to $99 million

  • The round was led by ICG's Life Sciences team with participation from existing investors

  • The funds will be used to expand the ongoing Phase 1/2 clinical trial of their lead immuno-oncology candidate, GRWD5769, into various solid tumors, and to expand their R&D for treatments for autoimmune disease indications

  • Grey Wolf's platform focuses on developing potent and selective oral ERAP1 inhibitors like GRWD5769, with a second inhibitor, GRWD0715, in preclinical development for autoimmune diseases

  • The company also leverages its neoantigen creation expertise with an ERAP2 drug discovery program and by targeting novel ERAP1 inhibitor generated cancer antigens.

      • ProblemHealthcare

      "Cancer patients have limited treatment options and many experience severe side effects. Current cancer immunotherapies have limited efficacy and can be expensive."

      Solution

      "Grey Wolf Therapeutics is developing novel oral therapies that target ERAP1, an enzyme that plays a crucial role in the presentation of cancer antigens to the immune system. By inhibiting ERAP1, Grey Wolf's therapies aim to improve the body's natural ability to fight cancer while minimizing side effects."

      Covered on